Exosomes · Lesson 18 of 18 · 3 min

Ethics of offering exosome therapy: consent, cost and marketing

The ethical ground rules for clinicians considering exosomes: informed consent for an investigational therapy, patient selection, cost, honest marketing and competency.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • Consent for an investigational therapy is a conversation, not a signature on a form.
  • Patient autonomy matters, but clinicians may decline treatments they judge inappropriate.
  • Access is distributed almost entirely by ability to pay, which raises a justice concern.
  • Appropriate marketing describes exosomes as investigational and discloses the lack of FDA approval.
  • No board certification or standardized training pathway exists for exosome therapy.
  • Chronic pain, hope and financial pressure can affect decisions even in competent adults.

Consent is different for investigational therapy

With an approved drug, consent focuses on whether known benefits outweigh known risks for this patient. With exosomes there are no FDA-approved products, limited long-term data, early-stage evidence and out-of-pocket costs that can reach thousands of dollars.

The patient needs to understand all of that. The course frames consent as a substantive dialogue covering investigational status, evidence limits, alternatives, realistic expectations, cost and the absence of any guarantee.

When patient demand meets clinical judgment

Competent adults have the right to make their own healthcare decisions. That right is not absolute. Clinicians may decline to provide an intervention they judge inappropriate or an unjustified departure from the standard of care.

A common case is the patient who wants exosomes before trying standard first-line treatments. Paying out of pocket does not by itself settle the question. Vulnerability from chronic pain and hope calls for safeguards.

Cost, access and marketing

Exosome therapy is generally paid for out of pocket. Access therefore depends almost entirely on ability to pay, which the course identifies as a justice problem.

Marketing ranges from appropriate to misleading to fraudulent, and it falls under FDA and FTC rules. Appropriate marketing describes exosome therapy as investigational, explains mechanisms without implying guaranteed benefit, presents outcomes as possibilities, and discloses that the FDA has not approved exosome products.

Professional responsibility

No formal board certification or standardized training pathway exists for exosome therapy. The lack of a formal requirement does not remove the ethical obligation to be competent.

At minimum, that means a working knowledge of exosome biology and the current evidence base. Exosome therapies are not FDA-approved for therapeutic use.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Structuring the consent conversation and documentation
  • Working through difficult patient-selection scenarios
  • Compliant versus problematic marketing language
  • Competency and scope-of-practice expectations

Common questions.

What should informed consent for exosome therapy cover?
Investigational status, the limits of the evidence, alternatives, realistic expectations, financial implications and the fact that no outcome is guaranteed.
Can I advertise exosome therapy?
Marketing is subject to FDA and FTC regulation. The course describes appropriate marketing as accurate, clear that the therapy is investigational, and explicit that the FDA has not approved exosome products.
Is there a certification for exosome therapy?
No formal board certification or standardized training pathway exists. Clinicians still have an ethical obligation to understand the science and the evidence.

Sources

  • Beauchamp, T. L., & Childress, J. F. (2019). Principles of Biomedical Ethics (8th ed.). Oxford University Press.
  • Marks, P. W., et al. (2017). Clarifying stem-cell therapy's benefits and risks. New England Journal of Medicine, 376(11), 1007-1009.
  • ISSCR. (2021). Guidelines for Stem Cell Research and Clinical Translation. International Society for Stem Cell Research.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.